Testosterone injections deliver testosterone into the muscle. The testosterone is then absorbed directly into the blood stream over time. The absorption period depends on the type of testosterone injected. Injections usually take place in the thighs, glutes or deltoid muscles.
Read on to learn about the most common forms of injectable testosterone, therapeutic dosages, pros and cons of testosterone injections, and injection demonstration resources.
Testosterone Injections
Two Most Common Types of Injectable Testosterone
The most common forms of injectable testosterone for testosterone replacement therapy (TRT) include testosterone enanthate (TE) and testosterone cypionate (TC). Testosterone enanthate and testosterone cypionate are modified forms of testosterone. Specifically, a carboxylic acid ester has been added to the 17-beta hydroxyl group. This attachment makes TE and TC less polar than free T. As a result, they have longer half-lives and are absorbed more slowly from the injection area. Once in the bloodstream, the ester is removed to yield free (active) T. Due to their long half-lives, both TE and TC provide a sustained release of testosterone into the bloodstream for one to two weeks. As a result, testosterone injections of TE or TC need only be administered every week or every other week.
Half-Lives of TE and TC
Testosterone enanthate possesses a half-life of roughly 8-10 days.7 Testosterone cypionate possesses a half-life of roughly 10-12 days.7 [Half-lives depend on a person’s own rate of metabolism, so they may vary.] Therefore, it takes approximately 8 to 10 days for the body to metabolize and clear half the concentration of the testosterone enanthate following an injection. As a result, users need only inject every week or every other week. Find resources on how to give testosterone shots below.
Dosing Regimens for TRT
The recommended dosing regimen of testosterone enanthate or testosterone cypionate for testosterone therapy is 75 to 100 mg every week or 150 to 200 mg every other week.1-5 Weekly injections are preferred because more frequent injections lower fluctuations in serum testosterone. About 30% of men treated for low testosterone use testosterone injections. [About 65% of men use testosterone gel.]6
Pros of Testosterone Injections
- Injectable testosterone is inexpensive if self-administered. The two most common forms (testosterone enanthate and testosterone cypionate) are both generic medications in the United States.
- Flexible dosing. Dosages can be changed with each injection, if necessary, to achieve optimal concentrations.
- Testosterone enanthate and testosterone cypionate only need to be injected every week or every other week. Also, a longer lasting version, testosterone undecanoate, is now available in the US. The FDA approved injectable testosterone undecanoate in 2014. Endo Pharmaceuticals will market it under the brand name Aveed. It will extend the period between injections to ten weeks after an initial ramp-up period. Find more information on Aveed below.
Cons of Testosterone Injections
- Testosterone injections do not mimic physiologic dosing. As a result, T levels can fluctuate in between injections. Fluctuations in testosterone are not ideal. These fluctuations can affect mood, emotional stability, and sexual activity.2 Shortening the interval between injections and lowering the dosage proportionally can minimize this cyclical nature of highs and lows. The longer lasting version of injectable testosterone, testosterone undecanoate, maintains T levels in normal ranges.
- Testosterone injections are more likely to cause an increased red blood cell count than other forms.
- Injection site pain is relatively common although injection site pain rarely indicates a problem.
- Need to visit a physician for testosterone injections if unable to self-administer at home.
Aveed: A Newly Approved, Slow Acting Injectable Testosterone
Recently, the US FDA approved injectable testosterone undecanoate (2014). Endo Pharmaceuticals will market it under the brand name Aveed. Testosterone undecanoate has actually been available under the brand name Nebido for over 10 years outside the US. Testosterone undecanoate is very slow acting. The drug provides a sustained release of testosterone into the bloodstream for up to 10 weeks.
In its Phase 3 Study, treatment with AVEED 750 mg maintained T levels in the normal range over 10 week dosing interval.6,14 The figure below illustrates T levels after the third injection. While testosterone undecanoate does not raise levels above normal, testosterone injections of TU still do not mimic physiologic dosing.
Suppliers
Both testosterone enanthate and testosterone cypionate are widely available in generic forms from compounding pharmacies. Also, most of the major low testosterone clinics use testosterone injections as the preferred testosterone replacement therapy administration method (See EMG’s Testosterone Resource Center for more information on the major low testosterone clinics). Testosterone undecanoate is marketed under the brand name Aveed by Endo Pharmaceuticals.
Injection Information
For injection information, the University of Michigan provides a detailed PDF primer on How to give a Testosterone Intramuscular (IM) Injection. A video demonstration can be found at LowTestosterone.com’s Intramuscular Injection Video. Also, ask your physician to explain and demonstrate the technique.
Common Esters Available for Testosterone Injections
Below is a discussion of common testosterone esters. The primary difference between esters is the rate at which testosterone enters the bloodstream following an injection. A slower release means fewer testosterone injections per year. Testosterone propionate is a fast-acting ester rarely used in TRT. Testosterone enanthate and testosterone cypionate are slow-acting injectable forms. They have been the predominant form used for TRT. Testosterone undecanoate is a newly approved form that is very slow-acting.
Testosterone Cypionate
Testosterone cypionate is a slow-acting injectable form of the androgen testosterone. Following deep intramuscular injection, the drug provides a sustained release of testosterone into the bloodstream for 2 to 3 weeks.14 Testosterone cypionate possesses a half-life of 10-12 days. The most commonly recommended dosing regimen for TRT is is 75 to 100 mg every week or 150 to 200 mg every other week. Typically, 26-52 injections are required per year.
Testosterone Enanthate
Similar to testosterone cypionate, testosterone enanthate is a slow-acting injectable form of the androgen testosterone. Following deep intramuscular injection, the drug provides a sustained release of testosterone into the bloodstream for 2 to 3 weeks.14 Testosterone enanthate possesses a half-life of 8-10 days. The most commonly recommended dosing regimen for TRT is is 75 to 100 mg every week or 150 to 200 mg every other week. Typically, 26-52 injections are required per year.
Testosterone Propionate
In comparison to testosterone enanthate and testosterone cypionate, testosterone propionate is a faster-acting form of the androgen testosterone. Testosterone propionate possesses a half-life of roughly 1-2 days. Therefore, testosterone propionate does not provide a sustained release. Due to this short half-life, it must be injected every other day or every third day. As a result, it is rarely used for TRT.
Testosterone Undecanoate
Testosterone undecanoate is very slow-acting injectable form of the androgen testosterone. Following deep intramuscular injection, the drug provides a sustained release of testosterone into the bloodstream for up to 10 weeks. Testosterone undecanoate has been available under the brand name Nebido for over 10 years in more than 80 countries. However, it was not approved for use in the US.
Recently, however, the US FDA approved injectable testosterone undecanoate (2014). Endo Pharmaceuticals will market it under the brand name Aveed. Aveed is a depot formulation of testosterone undecanoate (TU) indicated for long-term TRT. Testosterone injections of 750 mg Aveed maintain normal levels between 300 and 1000 ng/dL for up to 10 weeks. Following baseline administration of 750 mg, a second 750 mg dose is given at 4 weeks followed by 750 mg every 10 weeks thereafter.
Due to the very slow-acting nature, Aveed will offer men with low testosterone a more convenient treatment option than currently available preparations. The injection interval for TU, after the loading dose, is 10 weeks. This equates to approximately 5 injections per year. In comparison, testosterone gels require daily dosing and testosterone enanthate and testosterone cypionate require injections every other week (26 injections per year).
EMG’s TRT Resource: Types of Testosterone
External Resources: Medscape: Types of Testosterone
Updated: June 17, 2015
References1. Corona G, Rastrelli G, Forti G, Maggi M. Update in TRT for men. J Sex Med. Mar 2011; 8 (3): 639-654; quiz 655.
2. Miner MM. Low Testosterone Medscape CME Expert Column Series. Issue 3: Delivering Safe and Effective TRT. Medscape Education. 2011.
3. Edelstein D., Dobs A., Basaria A. Emerging drugs for hypogonadism. Expert Opin. Emerg. Drugs. 2006; 11(4): 685-707.
4. Bhasin S, Cunningham GR, Hayes FJ, et al. TRT in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6): 2536–2559.
5. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005; 26: 833-876.
6. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM348092.pdf
7. Dobs AS, Meinkle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate and testosterone cypionate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999; 84: 3469-3478.
8. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod. 1995; 10(4): 862-865.
9. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011; 165(5): 675-685.
10. Claustres M, Sultan C. Androgen and erythropoiesis: evidence for an androgen receptor in erythroblasts from human bone marrow cultures. Horm Res. 1988; 29 (1): 17-22.
11. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of TRT in nursing home men with low testosterone levels. J Am Geriatr Soc. Aug 1995; 43 (8): 899-901.
12. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res. Jul 1997; 2 (7): 293-298.
13. Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009; 94(6): 1910-1915.
14. Schulte-Beerbühl M, Nieschlag E. Comparison of T, DHT, LH, and FSH in serum after injection of testosterone enanthate of testosterone cypionate. 1980 Feb;33(2):201-3.